Xolair 150 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB26FBNNU
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,547
Award facts
- Contract value 100% obligated
- $1,547.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $1,547.40 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 150 mg/mL Xolair syringes. The delivery order, issued on October 29, 2025 with an ultimate completion date of November 20, 2025, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for Department of Defense healthcare operations.
The PPV-G GEN V contract, designated SPE2DR and valued at $499,999,999 with a completion date of December 31, 2036, authorizes the Defense Logistics Agency to issue delivery orders for comprehensive pharmaceutical products and medical consumables to support military healthcare facilities worldwide. DMS Pharmaceutical Group, registered in the System for Award Management since 2001, has demonstrated substantial performance as a critical supplier within the federal pharmaceutical supply chain, with a diverse product portfolio encompassing branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals. The Xolair delivery represents one of numerous orders issued to the vendor by the Defense Logistics Agency's Medical Supply Chain division, reflecting the company's established capability to fulfill specialized pharmaceutical requirements for Department of Defense operations.
Quick answers
Who was awarded contract SPE2DB26FBNNU?
SPE2DB26FBNNU was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 29, 2025.
How much is contract SPE2DB26FBNNU worth?
The government has obligated $1,547 on SPE2DB26FBNNU.
Is contract SPE2DB26FBNNU an order under another contract?
Yes. SPE2DB26FBNNU is a delivery order under SPE2DB24D9211, an indefinite delivery contract.
Was contract SPE2DB26FBNNU competed?
The extent of competition for SPE2DB26FBNNU was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award